Total Payments
$85,860
2024 Payments
$4,713
Companies
60
Transactions
1,139
Medicare Patients
3,386
Medicare Billing
$416,202
Payment Breakdown by Category
Other$49,998 (58.2%)
Food & Beverage$22,112 (25.8%)
Travel$7,886 (9.2%)
Research$5,385 (6.3%)
Education$478.91 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,998 | 21 | 58.2% |
| Food and Beverage | $22,112 | 1,069 | 25.8% |
| Travel and Lodging | $7,886 | 34 | 9.2% |
| Unspecified | $5,385 | 5 | 6.3% |
| Education | $478.91 | 10 | 0.6% |
Payments by Type
General
$80,475
1,134 transactions
Research
$5,385
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $31,813 | 140 | $0 (2024) |
| Merck Sharp & Dohme LLC | $20,891 | 50 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $15,833 | 35 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $2,373 | 118 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,157 | 164 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,655 | 73 | $0 (2024) |
| GENZYME CORPORATION | $1,292 | 52 | $0 (2024) |
| United Therapeutics Corporation | $982.29 | 38 | $0 (2024) |
| Genentech USA, Inc. | $952.07 | 47 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $645.45 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,713 | 208 | AstraZeneca Pharmaceuticals LP ($684.44) |
| 2023 | $3,951 | 167 | Actelion Pharmaceuticals US, Inc. ($705.82) |
| 2022 | $3,166 | 162 | Boehringer Ingelheim Pharmaceuticals, Inc. ($393.67) |
| 2021 | $1,482 | 81 | GlaxoSmithKline, LLC. ($342.53) |
| 2020 | $2,236 | 47 | Bayer HealthCare Pharmaceuticals Inc. ($1,324) |
| 2019 | $1,965 | 128 | Boehringer Ingelheim Pharmaceuticals, Inc. ($279.59) |
| 2018 | $31,311 | 197 | Actelion Pharmaceuticals US, Inc. ($20,584) |
| 2017 | $37,036 | 149 | Merck Sharp & Dohme Corporation ($18,093) |
All Payment Transactions
1,139 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.63 | General |
| Category: HFCWO | ||||||
| 12/20/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Airway Clearance Device | ||||||
| 12/19/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: PULMONOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: RESPIRATORY | ||||||
| 12/16/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $33.77 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $37.46 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $28.24 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/11/2024 | Vifor Pharma, Inc. | Zemaira (Drug) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/05/2024 | INOGEN, INC. | INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH (Device) | Food and Beverage | Cash or cash equivalent | $21.14 | General |
| Category: OXYGEN CONCENTRATOR | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.16 | General |
| 12/03/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $26.72 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $5.94 | General |
| Category: Narcoplepsy | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Respiratory | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Respiratory | ||||||
| 11/22/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Airway Clearance Device | ||||||
| 11/22/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $6.09 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $1.64 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Immunology | ||||||
| 11/19/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| QUERI EXTENSION - AC-052428 USA | Actelion Pharmaceuticals US, Inc. | $5,385 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 923 | 1,285 | $171,786 | $125,654 |
| 2022 | 11 | 975 | 1,269 | $159,612 | $117,872 |
| 2021 | 11 | 744 | 897 | $116,770 | $88,076 |
| 2020 | 14 | 744 | 927 | $111,352 | $84,601 |
Total Patients
3,386
Total Services
4,378
Medicare Billing
$416,202
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 280 | 435 | $77,865 | $56,484 | 72.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 143 | 323 | $38,114 | $29,155 | 76.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 95 | 95 | $20,532 | $15,359 | 74.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 64 | 66 | $11,286 | $8,841 | 78.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 61 | $9,287 | $5,926 | 63.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 78 | 85 | $3,910 | $2,447 | 62.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 41 | 44 | $2,552 | $1,903 | 74.6% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 66 | 74 | $2,442 | $1,837 | 75.2% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 41 | 44 | $2,376 | $1,831 | 77.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $2,150 | $973.84 | 45.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 32 | 32 | $864.00 | $617.40 | 71.5% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 12 | 12 | $408.00 | $279.85 | 68.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 274 | 435 | $77,865 | $56,973 | 73.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 135 | 244 | $25,446 | $19,785 | 77.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 104 | 104 | $22,776 | $16,870 | 74.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 47 | $9,233 | $7,303 | 79.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 58 | $7,424 | $5,544 | 74.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 104 | 116 | $5,336 | $3,160 | 59.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 61 | 62 | $3,596 | $2,576 | 71.6% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 60 | 61 | $3,294 | $2,454 | 74.5% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 98 | 106 | $3,498 | $2,428 | 69.4% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 20 | 20 | $680.00 | $468.77 | 68.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 15 | 16 | $464.00 | $310.50 | 66.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 199 | 266 | $47,620 | $35,670 | 74.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 136 | 153 | $19,489 | $13,784 | 70.7% |
About Dr. David Baratz, MD
Dr. David Baratz, MD is a Internal Medicine healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104879436.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Baratz, MD has received a total of $85,860 in payments from pharmaceutical and medical device companies, with $4,713 received in 2024. These payments were reported across 1,139 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($49,998).
As a Medicare-enrolled provider, Baratz has provided services to 3,386 Medicare beneficiaries, totaling 4,378 services with total Medicare billing of $416,202. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Pulmonary Disease, Sleep Medicine
- Location Phoenix, AZ
- Active Since 05/18/2006
- Last Updated 10/07/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1104879436
Products in Payments
- BELSOMRA (Drug) $20,442
- Adempas (Drug) $15,833
- OPSUMIT MACITENTAN (Drug) $14,837
- UPTRAVI (Drug) $6,500
- DUPIXENT (Biological) $1,781
- OPSUMIT (Drug) $1,222
- TRELEGY ELLIPTA (Drug) $886.45
- STIOLTO RESPIMAT (Drug) $783.62
- NUCALA (Biological) $747.04
- ACTHAR (Biological) $717.80
- Xolair (Biological) $672.25
- TYVASO (Drug) $612.40
- Arikayce (Drug) $485.54
- TEZSPIRE (Biological) $448.07
- SYMBICORT (Drug) $426.58
- SMARTVEST (Device) $411.81
- Wakix (Drug) $339.28
- XYWAV (Drug) $328.96
- FASENRA (Drug) $328.41
- OFEV (Drug) $327.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Phoenix
Frank Lovecchio, D.o, D.O
Internal Medicine — Payments: $973,948
Internal Medicine $973,948
Dr. Rajkumar Sugumaran, M.d, M.D
Internal Medicine — Payments: $910,158
Internal Medicine $910,158
Dr. Javier Munoz, M.d., M.s., F.a.c.p, M.D., M.S., F.A.C.P
Internal Medicine — Payments: $858,556
Internal Medicine $858,556
Nasser Hajaig, Md, MD
Internal Medicine — Payments: $651,570
Internal Medicine $651,570
Brian Porvin, Do, DO
Internal Medicine — Payments: $326,640
Internal Medicine $326,640
Mark Gotfried, Md, MD
Internal Medicine — Payments: $307,917
Internal Medicine $307,917